Guidelines Open access

The Italian Society of Rheumatology clinical practice guidelines for the management of vaccines in adult patients with rheumatic diseases

Authors

Published
9 April 2026
Section
Guidelines
DOI
10.4081/reumatismo.2026.1895

Abstract

Objective. Rheumatic and musculoskeletal diseases (RMDs) represent a significant public health challenge in Italy. RMDs are often chronic and lead to increased morbidity and mortality, partly due to an increased risk of infections. Patients with RMDs and those on immunosuppressive therapy show a higher susceptibility to vaccine-preventable diseases and to serious complications in case of infection. Therefore, vaccination is a crucial tool to reduce these risks. This guideline was developed by the Italian Society of Rheumatology and aimed to provide updated national recommendations for clinical practice on vaccinations in adult patients with RMDs.

Methods. The GRADE ADOLOPMENT approach to combine adoption, adaptation, or de novo development of recommendations was used, and the 2022 American College of Rheumatology (ACR) guideline on vaccinations in RMDs was used as reference. The development process included an updated systematic review of the available evidence and an assessment of the ACR guidelines and their adaptability to the Italian context, followed by a discussion with experts in rheumatology and public health and representatives of healthcare professionals and patients.

Results. A set of recommendations was developed, and special attention was given to the current vaccination schedule and to the adjustment of anti-rheumatic drugs to optimize the response to vaccines.

Conclusions. This guideline is a step forward in enhancing management and clinical practice for RMD patients in Italy and provides specific and evidence-based indications for infection prevention through vaccination. Their use is intended to promote health and alleviate the burden of morbidity and mortality in this vulnerable population.

Keywords

References

  1. Salaffi F, De Angelis R, Grassi W, et al. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23: 819-28.
  2. Sebbag E, Felten R, Sagez F, et al. The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database. Ann Rheum Dis 2019; 78: 844-8. DOI: https://doi.org/10.1136/annrheumdis-2019-215142
  3. Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open 2019; 5: e000935. DOI: https://doi.org/10.1136/rmdopen-2019-000935
  4. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013; 347: f5061. DOI: https://doi.org/10.1136/bmj.f5061
  5. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 2012; 13: 158. DOI: https://doi.org/10.1186/1471-2474-13-158
  6. Consiglio dei Ministri. Intesa, ai sensi dell’articolo 8, comma 6, della Legge 5 giugno 2003, n. 131, tra il governo, le regioni e le province autonome di trento e di bolzano, sul documento recante «Piano Nazionale Di Prevenzione Vaccinale (PNPV) 2023-2025» e sul documento recante «Calendario Nazionale Vaccinale». Rep. Atti n. 193/CSR del 2 agosto 2023. Gazzetta Ufficiale Serie Generale, n. 194, 21/08/2023. [Document in Italian].
  7. Near AM, Tse J, Young-Xu Y, et al. Burden of influenza hospitalization among high-risk groups in the United States. BMC Health Serv Res 2022; 22: 1209. DOI: https://doi.org/10.1186/s12913-022-08586-y
  8. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 1074-81. DOI: https://doi.org/10.1002/art.23913
  9. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and musculoskeletal Diseases. Arthritis Rheumatol 2023; 75: 333-48. DOI: https://doi.org/10.1002/art.42386
  10. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol 2023; 75: E1-16. DOI: https://doi.org/10.1002/art.42372
  11. Istituto Superiore di Sanità. Raccomandazioni della SIR sulle vaccinazioni nei pazienti affetti da malattie reumatologiche. Sistema Nazionale Linee Guida. Istituto Superiore di Sanità. Available from: https://www.iss.it/-/vaccinazioni-in-pazienti-affetti-da-malattie-reumatologiche. Accessed: 2/02/2025.
  12. Guerrini G, Franzetti F, Giacomelli R, et al. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. Clin Exp Rheumatol 2020; 38: 245-56. DOI: https://doi.org/10.55563/clinexprheumatol/hj69ne
  13. Schünemann HJ, Wiercioch W, Brozek J, et al. GRADE evidence to decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol 2017; 81: 101-10. DOI: https://doi.org/10.1016/j.jclinepi.2016.09.009
  14. Centro Nazionale per l’Eccellenza Clinica, Istituto Superiore di Sanità. Manuale metodologico per la produzione di linee guida di pratica clinica, versione 1.3.3, marzo 2023. Available from: https://www.iss.it/-/Snlg-Manuale-Metodologico. Accessed: 18/02/2024.
  15. Dewidar O, Lotfi T, Langendam M, et al. Which actionable statements qualify as good practice statements in Covid-19 guidelines? A systematic appraisal. BMJ Evid Based Med 2022; 27: 361-9. DOI: https://doi.org/10.1136/bmjebm-2021-111866
  16. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919. DOI: https://doi.org/10.1136/bmj.i4919
  17. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: I4898. DOI: https://doi.org/10.1136/bmj.l4898
  18. Brouwers MC, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 2010; 51: 421-4. DOI: https://doi.org/10.1016/j.ypmed.2010.08.005
  19. Park JK, Lee YJ, Shin K, et al. a multicenter, prospective, randomized, parallel-group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis. Arthritis Rheumatol 2023; 75: 171-7. DOI: https://doi.org/10.1002/art.42318
  20. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79: 39-52. DOI: https://doi.org/10.1136/annrheumdis-2019-215882
  21. Alunno A, Carubbi F, Tan AL, et al. COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases: insights from the COVAD study. Rheumatol Int 2024; 44: 1725-31. DOI: https://doi.org/10.1007/s00296-024-05654-w

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.